About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company founded in 2012 and a wholly-owned subsidiary of Eli Lilly and Company. We specialize in gene therapy, biotechnology, rare diseases, ophthalmology, and retina research.
We aim to make gene therapy a standard treatment for common eye diseases, developing cures to restore vision and prevent blindness. We use our proprietary intravitreal (IVT) platform to create lasting, single-administration therapies. These treatments are designed for use in doctors’ offices, aiming to eliminate the need for frequent eye injections.
We are currently testing our gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022), as a one-time IVT injection for patients with neovascular or wet age-related macular degeneration (wet AMD). Ixo-vec uses a proprietary, next-generation adeno-associated virus (AAV) vector platform. This treatment is designed to turn retinal cells into “biofactories” that continuously produce and release therapeutic doses of aflibercept, a proven anti-VEGF treatment.
Mission & Values
Our mission is to make gene therapy a new standard treatment for debilitating eye diseases, especially those that cause vision loss. We aim to develop cures that restore sight and prevent blindness.
Our core values are:
- Lead with Integrity: We take individual and collective responsibility, prioritize patients, and make decisions based on evidence.
- Pioneer with Patients: We use science, technology, and our expertise to innovate and improve products that preserve patients’ sight worldwide.
- Strive Together: We set high goals, tackle complex issues with diverse perspectives, share decision-making, and collaborate.
These values guide how we conduct business, approach patient care, apply science to medicine, and operate as a company. We also consider environmental, social, and governance objectives in our decisions.
Team & Culture
We have 51-200 employees. We see our team as “visionaries and disruptors” dedicated to helping patients live full lives. Our culture emphasizes going the extra mile to develop and deliver functional cures for debilitating eye diseases.
Frequently Asked Questions
Adverum Biotechnologies is developing gene therapies for highly prevalent ocular diseases. Its lead candidate, ixoberogene soroparvovec (Ixo-vec), is an investigational gene therapy for patients with neovascular or wet age-related macular degeneration (wet AMD). Ixo-vec is designed as a one-time, single-administration intravitreal (IVT) therapy.
Adverum Biotechnologies’ global mission is to establish gene therapy as a new standard of care for debilitating ocular diseases, particularly the leading causes of vision loss. The company aspires to develop functional cures to restore vision and prevent blindness.
The core values include Lead with Integrity, which involves taking responsibility and making evidence-based decisions; Pioneer with Patients, focusing on innovation to preserve sight; and Strive Together, which emphasizes collaboration and diverse perspectives to address complex challenges. These values also encompass integrating environmental, social, and governance objectives.
Adverum Biotechnologies describes its team as “visionaries and disruptors” who work to help patients. The culture emphasizes going beyond to develop and deliver functional cures for debilitating ocular diseases, with an aim to improve patients’ lives.
Adverum Biotechnologies was founded in 2012.
Adverum Biotechnologies is active in the Gene Therapy, Biotechnology, Rare Diseases, Ophthalmology, and Retina markets.
Adverum Biotechnologies has 51-200 employees.
Adverum Biotechnologies hires in 🇺🇸 United States.
Yes! Adverum Biotechnologies is actively hiring with 1 open remote job available now.
Yes, Adverum Biotechnologies is a remote-first company.
Adverum Biotechnologies's website is www.adverum.com .
You can find Adverum Biotechnologies on X (Twitter) and LinkedIn .
1 remote jobs at Adverum Biotechnologies
Explore latest remote opportunities and join a team that values work flexibility.
Remote companies like Adverum Biotechnologies
Find your next opportunity with companies that specialize in Gene Therapy, Biotechnology, Rare Diseases, and Ophthalmology. Explore remote-first companies like Adverum Biotechnologies that prioritize flexible work and home-office freedom.
REGENXBIO
A clinical-stage biotechnology company developing gene therapies for retinal and rare diseases
4D Molecular Therapeutics
Develops and commercializes gene therapeutic products for serious unmet medical conditions using a proprietary vector discovery platform.
Arcellx
A clinical-stage biotechnology company developing cell therapies for cancer and autoimmune diseases.
Kyverna Therapeutics
A clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases.
Arvinas
Clinical-stage biotechnology company developing targeted protein degradation therapies for serious diseases.
Alector
A late-stage clinical biotechnology company developing therapies for neurodegenerative diseases.
Project: Career Search
Rev. 2026.2
[ Remote Jobs ]
Direct Access
We source jobs directly from 21,000+ company career pages. No intermediaries.
Discover Hidden Jobs
Unique jobs you won't find on other job boards.
Advanced Filters
Filter by category, benefits, seniority, and more.
Priority Job Alerts
Get timely alerts for new job openings every day.
Manage Your Job Hunt
Save jobs you like and keep a simple list of your applications.